About PAION

PAION AG is a publicly listed specialty pharmaceutical with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK and China for procedural sedation and in Japan and South Korea for general anesthesia.

 

In addition to Byfavo® (remimazolam), PAION has two additional products, GIAPREZA® (angiotensin II) and  XERAVA® (eravacycline), in its portfolio. GIAPREZA® is a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies, and was launched in July 2021. XERAVA® is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

 

PAION’s mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare.


PAION is headquartered in Aachen (Germany).

PAION AG is listed on the Frankfurt Stock Exchange (Prime Standard Regulated Market, ticker symbol PA8, ISIN DE000A0B65S3).